2,412 reports of this reaction
6.9% of all VALBENAZINE reports
#2 most reported adverse reaction
SOMNOLENCE is the #2 most commonly reported adverse reaction for VALBENAZINE, manufactured by Neurocrine Biosciences, Inc.. There are 2,412 FDA adverse event reports linking VALBENAZINE to SOMNOLENCE. This represents approximately 6.9% of all 34,810 adverse event reports for this drug.
Patients taking VALBENAZINE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is moderately reported among VALBENAZINE users, representing a notable but not dominant share of adverse events.
In addition to somnolence, the following adverse reactions have been reported for VALBENAZINE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 2,412 FDA reports for VALBENAZINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 6.9% of all adverse event reports for VALBENAZINE, making it one of the most commonly reported side effect.
If you experience somnolence while taking VALBENAZINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.